Stock VIRI VIRIOS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Virios Therapeutics, Inc.

Equities

VIRI

US92829J1043

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/06/2024 am IST 		5-day change 1st Jan Change
0.2386 USD -4.25% Intraday chart for Virios Therapeutics, Inc. -4.18% -58.50%
20/06 Maxim Initiates Virios Therapeutics at Buy Rating With $1 Price Target MT
20/05 Top Midday Decliners MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Maxim Initiates Virios Therapeutics at Buy Rating With $1 Price Target
MT
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
AQ
Top Midday Decliners
MT
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
AQ
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Ahead of NVIDIA Earnings due Wednesday
MT
Virios Therapeutics Prices $1.7 Million Common Stock Offering
MT
Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
AQ
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
AQ
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
AQ
Transcript : Virios Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
Virios Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
AQ
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
AQ
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
AQ
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
AQ
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
AQ
Virios Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
AQ
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
AQ
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VIRI Stock
  4. News Virios Therapeutics, Inc.